ASND
Ascendis Pharma A/S · Healthcare · Biotechnology
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q2 2024
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q2 2026 | 106 | +15 | 28.56M | $7.62B | +25 | −10 |
| Q1 2026 | 92 | -6 | 28.38M | $6.48B | +8 | −14 |
| Q4 2025 | 96 | -1 | 34.58M | $7.37B | — | −1 |
| Q3 2025 | 15 | 0 | 10.69M | $2.13B | +1 | −1 |
| Q2 2025 | 12 | -2 | 9.16M | $1.58B | — | −2 |
| Q1 2025 | 12 | +1 | 5.48M | $853.40M | +1 | — |
| Q4 2024 | 11 | -2 | 5.30M | $729.95M | — | −2 |
| Q3 2024 | 12 | +1 | 6.24M | $930.97M | +2 | −1 |
| Q2 2024 | 11 | — | 7.02M | $958.03M | — | — |
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 2.61M | — | $356.34M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 2.61M | — | $356.34M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 2.61M | — | $356.34M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 2.61M | — | $356.34M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 2.61M | — | $356.34M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 2.61M | — | $356.34M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 2.61M | — | $356.34M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 1.78M | — | $243.32M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 820.51K | — | $111.90M | 0.2% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 537.76K | — | $73.34M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 537.76K | — | $73.34M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Millennium Management ✦ | 473.45K | — | $64.57M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 281.54K | — | $38.40M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 281.54K | — | $38.40M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 255.32K | — | $34.82M | 0.1% | n/c | 1 | SEC ↗ |
| 16 | Soros Fund Management ✦ | 100.00K | — | $13.64M | 0.4% | n/c | 1 | SEC ↗ |
| 17 | Baillie Gifford ✦ | 71.07K | — | $9.69M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Baillie Gifford ✦ | 71.07K | — | $9.69M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Baillie Gifford ✦ | 71.07K | — | $9.69M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Geode Capital Management ✦ (pasif) | 57.79K | — | $7.88M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Marshall Wace ✦ | 30.29K | — | $4.13M | 0.0% | n/c | 1 | SEC ↗ |
"Bobot mereka" = porsi posisi dari total nilai ekuitas 13F yang dilaporkan manajer tersebut — ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Tidak ada pembeli terlacak baru kuartal ini. |
Telah keluar
| Tidak ada keluar yang terlacak kuartal ini. |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 8 pemegang, 7.94M saham, $34.76M dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Apa lagi yang paling sering dimiliki oleh pemegang efek ini yang dilacak — berdasarkan jumlah kepemilikan bersama, bukan hubungan fundamental.
Pembelian di pasar terbuka (P)
Director · 1.10K lbr @ 245.85 · $270,435
Director · 900 lbr @ 246.91 · $222,219
Penjualan di pasar terbuka (S)
Tidak ada penjualan insider di pasar terbuka dalam jendela cakupan kami.
Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi